1-3 of 3
Neil Martin Kogut, M.D.
Close
Sort by
Journal Articles

Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.

Sahebi Firoozeh, MD, Jeffery R. Schriber, M.D., Ricardo Spielberger, M.D., Ji-Lian Cai, M.D., Neil Martin Kogut, M.D., Peter M. Falk, M.D., Pablo Miguel Parker, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Chatchada Karanes, M.D., Dajun Qian, PhD., Stephen J. Forman, M.D., George Somlo, M.D.
Journal: Blood
Blood (2007) 110 (11): 3030.
https://doi.org/10.1182/blood.V110.11.3030.3030
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

Auayporn P. Nademanee, MD, Amrita Krishnan, M.D, Nicole Tsai, MS, MPH, Joycelynne Palmer, Ph.D., Arturo Molina, M.D., Henry C. Fung, M.D., David Yamauchi, M.D, Neil Martin Kogut, M.D., Stephen J. Forman, M.D., Andrew Raubitschek, M.D.
Journal: Blood
Blood (2006) 108 (11): 327.
https://doi.org/10.1182/blood.V108.11.327.327
Published: 2006
Journal Articles

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Auayporn P. Nademanee, MD, Jasmine M. Zain, M.D., Joycelynne Palmer, Ph.D., Nicole Tsai, M.S., M.P.H., Neil Martin Kogut, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Roberto Rodriguez, M.D., Eileen Patricia Smith, M.D., Stephen J. Forman, M.D.
Journal: Blood
Blood (2006) 108 (11): 3060.
https://doi.org/10.1182/blood.V108.11.3060.3060
Published: 2006